News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
109last 24h
3127last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Barchart80d agobearish
SMCI Stock Alert: What to Know as Super Micro Computer Wraps InvestigationSimply Wall St.81d agoneutral
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP TherapySimply Wall St.81d agobearish
The Bull Case For Alibaba (BABA) Could Change Following New Lawsuits Targeting Its AI And DisclosuresMarketBeat82d agobullish
Magnite Sees CTV Surge and Google Antitrust Remedies as Growth CatalystsSimply Wall St.82d agobearish
UnitedHealth Group (UNH) Hit With Investor Lawsuit Over Governance And Cybersecurity ClaimsStocktwits82d agoneutral
Apple Overhauls EU App Store Policies to Settle Long-Standing Antitrust DisputeThe Wall Street Journal82d agoneutral
Apple to Change Terms for App Developers to Appease EU’s Antitrust OfficialsSimply Wall St.82d agobearish
Monolithic Power Systems (MPWR) Is Facing A Shareholder Governance InvestigationThe Wall Street Journal82d agobearish
The Morning Risk Report: L3Harris Ousts CEO After Investigation Into ConductInsider Monkey83d agobullish
Guardant Health (GH) Surges on FDA Approval and Cancer Screening MomentumInvestor's Business Daily83d agobearish
Stellantis Recalls Almost 1 Million Cars; Stock Falls To All-Time LowInvestor's Business Daily83d agobearish
L3Harris Replaces CEO After Conduct Investigation, Shares RetreatSimply Wall St.83d agobearish
Peabody Energy (BTU) Faces Centurion Lawsuit, Is The Stock Still Cheap?Simply Wall St.84d agobearish
Is Peabody Energy’s (BTU) Centurion Lawsuit Quietly Reframing Its Long-Term Coal Production Narrative?Motley Fool85d agobearish
Alphabet Is Facing Thousands of Lawsuits. History Says This Is What May HappenSimply Wall St.86d agoneutral
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval LandsSimply Wall St.86d agobullish
Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?